#USA #Seattle #Huxley Medical #SANSA #Heart Disorders

Huxley Medical at SLEEP 2025: Pioneering Sleep Disorder Diagnostics

In the vibrant city of Seattle during the annual meeting of the Associated Professional Sleep Societies (APSS) from June 8-11, 2025, Huxley Medical shared crucial insights from their SANSA diagnostic platform. This commercial-stage medical technology company has laid out findings from three scientific abstracts that underline SANSA’s robust clinical capabilities in detecting sleep and heart disorders.

Innovations in Central Sleep Apnea Detection

At the forefront of the presentation was a new algorithm developed to enhance the detection of central sleep apnea (CSA) through SANSA. This algorithm was rigorously tested and compared against traditional in-lab polysomnography, showing impressive results. In a study involving 326 participants, SANSA not only met but frequently exceeded established benchmarks for home sleep apnea tests, leading to promising conclusions for this innovative diagnostic approach.

Relationships of Sleep Apnea with Arrhythmia

Huxley Medical's research included two enlightening studies that explored the intricate link between sleep apnea and arrhythmias, emphasizing SANSA's unique ability to furnish comprehensive data on underlying cardiac issues. The first study monitored a group of 153 patients suspected of sleep-disordered breathing (SDB), revealing that about one-third (33%) experienced clinically significant arrhythmias, with a noteworthy 20% of these patients unaware of their condition prior to testing.
In a subsequent study involving a smaller cohort of 30 patients undergoing Holter monitoring, SANSA findings indicated that nearly two-thirds experienced SDB, and an alarming 86% of those with atrial fibrillation (AF) were diagnosed with the condition. These results underscore the essential need to assess arrhythmias and other cardiac comorbidities in conjunction with home sleep evaluations.

Collaborative Research Efforts

These groundbreaking studies were conducted in collaboration with esteemed institutions such as Penn State University, the Mayo Clinic, and the University of Michigan, forming a coalition of researchers dedicated to advancing knowledge in sleep medicine. Dr. Rami Khayat, MD, who leads the Division of Pulmonary, Allergy, and Critical Care Medicine at Penn State, expressed optimism regarding SANSA’s diagnostic potential. He stated, "These data solidify SANSA's role as a multifunctional remote diagnostic tool, enabling the differentiation between obstructive and central sleep apnea and their connections to common comorbid cardiac conditions. These insights could significantly improve patient care efficiency."

Enhancing Clinical Practice with SANSA

Chris Lee, PhD, Huxley Medical's CEO, further articulated the transformative nature of SANSA’s capabilities, which allow clinicians to better understand and manage sleep disorders in tandem with heart health. Traditionally, these interconnected ailments have been dealt with separately, but SANSA’s comprehensive diagnostic approach promises a more unified strategy for treatment.

Conclusion: A Future of Integrated Healthcare

As Huxley Medical moves forward in their mission to innovate diagnostic tools that cater to patients' needs, the data presented at SLEEP 2025 lays a significant foundation for future advancements in sleep medicine. With continued collaboration and research, SANSA stands as a beacon of hope for the efficient management of sleep and heart conditions—two areas of healthcare that have long required an integrative approach.
For more information, visit Huxley Medical’s Official Website.

Note: Central sleep apnea performance has not yet been evaluated by the FDA. The diagnostic ECG's review is currently under FDA assessment.